659 related articles for article (PubMed ID: 23584477)
1. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
2. Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer.
Wu DW; Liu WS; Wang J; Chen CY; Cheng YW; Lee H
Clin Cancer Res; 2011 Apr; 17(7):1895-905. PubMed ID: 21325288
[TBL] [Abstract][Full Text] [Related]
3. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug.
Wang SP; Wang WL; Chang YL; Wu CT; Chao YC; Kao SH; Yuan A; Lin CW; Yang SC; Chan WK; Li KC; Hong TM; Yang PC
Nat Cell Biol; 2009 Jun; 11(6):694-704. PubMed ID: 19448627
[TBL] [Abstract][Full Text] [Related]
4. Mdm2 increases cellular invasiveness by binding to and stabilizing the Slug mRNA.
Jung CH; Kim J; Park JK; Hwang SG; Moon SK; Kim WJ; Um HD
Cancer Lett; 2013 Jul; 335(2):270-7. PubMed ID: 23438693
[TBL] [Abstract][Full Text] [Related]
5. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
[TBL] [Abstract][Full Text] [Related]
6. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
[TBL] [Abstract][Full Text] [Related]
7. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
8. Ling Zhi-8 reduces lung cancer mobility and metastasis through disruption of focal adhesion and induction of MDM2-mediated Slug degradation.
Lin TY; Hsu HY
Cancer Lett; 2016 Jun; 375(2):340-348. PubMed ID: 26992741
[TBL] [Abstract][Full Text] [Related]
9. Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers.
Wu YH; Tsai Chang JH; Cheng YW; Wu TC; Chen CY; Lee H
Oncogene; 2007 Jul; 26(33):4761-73. PubMed ID: 17325666
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation.
Cheng YW; Wu MF; Wang J; Yeh KT; Goan YG; Chiou HL; Chen CY; Lee H
Cancer Res; 2007 Nov; 67(22):10686-93. PubMed ID: 18006810
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.
Wu HH; Chu YC; Wang L; Tsai LH; Lee MC; Chen CY; Shieh SH; Cheng YW; Lee H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S336-47. PubMed ID: 22688662
[TBL] [Abstract][Full Text] [Related]
12. Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway.
Lv H; Liu R; Fu J; Yang Q; Shi J; Chen P; Ji M; Shi B; Hou P
Cell Cycle; 2014; 13(18):2962-74. PubMed ID: 25486483
[TBL] [Abstract][Full Text] [Related]
13. Loss of TIMP-3 promotes tumor invasion via elevated IL-6 production and predicts poor survival and relapse in HPV-infected non-small cell lung cancer.
Wu DW; Tsai LH; Chen PM; Lee MC; Wang L; Chen CY; Cheng YW; Lee H
Am J Pathol; 2012 Nov; 181(5):1796-806. PubMed ID: 22982189
[TBL] [Abstract][Full Text] [Related]
14. XPC inhibits NSCLC cell proliferation and migration by enhancing E-Cadherin expression.
Cui T; Srivastava AK; Han C; Yang L; Zhao R; Zou N; Qu M; Duan W; Zhang X; Wang QE
Oncotarget; 2015 Apr; 6(12):10060-72. PubMed ID: 25871391
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
16. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma.
Shih JY; Tsai MF; Chang TH; Chang YL; Yuan A; Yu CJ; Lin SB; Liou GY; Lee ML; Chen JJ; Hong TM; Yang SC; Su JL; Lee YC; Yang PC
Clin Cancer Res; 2005 Nov; 11(22):8070-8. PubMed ID: 16299238
[TBL] [Abstract][Full Text] [Related]
17. Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer.
Wang HH; Wang YC; Wu DW; Hung CS; Chen CY; Lee H
Tumour Biol; 2017 Apr; 39(4):1010428317694316. PubMed ID: 28378642
[TBL] [Abstract][Full Text] [Related]
18. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
19. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
[TBL] [Abstract][Full Text] [Related]
20. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
